Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.
CREATE Medicines is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.
Cardiosense is a digital biomarker platform that provides multi-sensor devices and proprietary algorithms to detect early signs of diseases.
RapidPulse is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke
Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies.
WalletFi is the Subscription Management solution for Financial Institutions and Fintechs
Neuro Tronik develops a medical device as an alternative for the drugs used currently to treat heart failures.
GrayBug is a biopharmaceutical company that develops transformative medicines for ocular diseases.
Iris Healthcare delivers the industry’s most comprehensive Advance Care Planning (ACP) solution.
Nursegrid is a create digital communication and collaboration tools.
Rodin Therapeutics develops novel therapeutics for neurological disorders by applying insights of epigenetics.
Curoverse employs open-source software to offer management, computation, and sharing services for genomic and biomedical data.
Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Sideris Pharmaceuticals is focused on the development of therapeutics for the treatment of transfusion-related iron overload.
Pathfinder Therapeutics offers tools and solutions to annihilate infectious diseases and cancers.
Hatteras Venture Partners has invested in 63 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Hatteras Venture Partners's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical Device, Pharmaceutical. The firm invests across 22 different industry categories.
Among tracked funding rounds, GrayBug received $80.0M in a Series C round. Hatteras Venture Partners's total known invested capital is $2.0B.
Hatteras Venture Partners's average investment size is $35.7M across its portfolio of 63 companies.
Recent Hatteras Venture Partners portfolio additions include Clearside Biomedical, CREATE Medicines, Cardiosense, RapidPulse, Code Biotherapeutics. These companies were founded in 2020 or later.